{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:35:08Z","timestamp":1789943708077,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"28","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,7,14]]},"DOI":"10.1038\/onc.2015.438","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T11:02:38Z","timestamp":1450090958000},"page":"3705-3717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["CBP\/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells"],"prefix":"10.1038","volume":"35","author":[{"given":"Y","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Masiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"McMillian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Smbatyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-L","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"BFonc2015438_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","volume":"35","author":"FJ Giles","year":"2008","unstructured":"Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T et al. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 2008; 35: S1\u2013S17.","journal-title":"Semin Oncol"},{"key":"BFonc2015438_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM . Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 2013; 13: 515\u2013529.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFonc2015438_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","volume":"91","author":"KN Rice","year":"2010","unstructured":"Rice KN, Jamieson CH . Molecular pathways to CML stem cells. Int J Hematol 2010; 91: 748\u2013752.","journal-title":"Int J Hematol"},{"key":"BFonc2015438_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657\u2013667.","journal-title":"N Engl J Med"},{"key":"BFonc2015438_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"Fodde R, Brabletz T . Wnt\/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150\u2013158.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc2015438_CR6","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013; 121: 4175\u20134183.","journal-title":"Blood"},{"key":"BFonc2015438_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","volume":"10","author":"FH Heidel","year":"2012","unstructured":"Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L et al. Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012; 10: 412\u2013424.","journal-title":"Cell Stem Cell"},{"key":"BFonc2015438_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528\u2013541.","journal-title":"Cancer Cell"},{"key":"BFonc2015438_CR9","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794\u20132799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR10","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/sj.onc.1208433","volume":"24","author":"H Ma","year":"2005","unstructured":"Ma H, Nguyen C, Lee KS, Kahn M . Differential roles for the coactivators CBP and p300 on TCF\/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24: 3619\u20133631.","journal-title":"Oncogene"},{"key":"BFonc2015438_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1182\/blood-2011-04-351239","volume":"118","author":"E Park","year":"2011","unstructured":"Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191\u20132199.","journal-title":"Blood"},{"key":"BFonc2015438_CR12","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.leukres.2008.11.013","volume":"33","author":"M Pehlivan","year":"2009","unstructured":"Pehlivan M, Sercan Z, Sercan HO . sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res 2009; 33: 1062\u20131067.","journal-title":"Leuk Res"},{"key":"BFonc2015438_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2010.10.032","volume":"18","author":"J Yeung","year":"2010","unstructured":"Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. \u03b2-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606\u2013618.","journal-title":"Cancer Cell"},{"key":"BFonc2015438_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nature03319","volume":"434","author":"T Reya","year":"2005","unstructured":"Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature 2005; 434: 843\u2013850.","journal-title":"Nature"},{"key":"BFonc2015438_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1083\/jcb.149.2.249","volume":"149","author":"KI Takemaru","year":"2000","unstructured":"Takemaru KI, Moon RT . The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000; 149: 249\u2013254.","journal-title":"J Cell Biol"},{"key":"BFonc2015438_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/emboj\/19.8.1839","volume":"19","author":"A Hecht","year":"2000","unstructured":"Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R . The p300\/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J 2000; 19: 1839\u20131850.","journal-title":"EMBO J"},{"key":"BFonc2015438_CR17","doi-asserted-by":"publisher","first-page":"14789","DOI":"10.1073\/pnas.232568499","volume":"99","author":"VI Rebel","year":"2002","unstructured":"Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM . Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA 2002; 99: 14789\u201314794.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.stem.2008.06.019","volume":"3","author":"A Marson","year":"2008","unstructured":"Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132\u2013135.","journal-title":"Cell Stem Cell"},{"key":"BFonc2015438_CR19","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/emboj.2013.127","volume":"32","author":"P Wend","year":"2013","unstructured":"Wend P, Fang L, Zhu Q, Schipper JH, Loddenkemper C, Kosel F et al. Wnt\/\u03b2-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J 2013; 32: 1977\u20131989.","journal-title":"EMBO J"},{"key":"BFonc2015438_CR20","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/onc.2013.169","volume":"33","author":"EJ Gang","year":"2014","unstructured":"Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S et al. Small-molecule inhibition of CBP\/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2014; 33: 2169\u20132178.","journal-title":"Oncogene"},{"key":"BFonc2015438_CR21","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1093\/nar\/gkq184","volume":"38","author":"YF Ramos","year":"2010","unstructured":"Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res 2010; 38: 5396\u20135408.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2015438_CR22","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/MCB.05830-11","volume":"31","author":"WI Chan","year":"2011","unstructured":"Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol. Cell Biol. 2011; 31: 5046\u20135060.","journal-title":"Mol. Cell Biol."},{"key":"BFonc2015438_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/30538","volume":"393","author":"H Kawasaki","year":"1998","unstructured":"Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 1998; 393: 284\u2013289.","journal-title":"Nature"},{"key":"BFonc2015438_CR24","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1073\/pnas.0404875101","volume":"101","author":"KH Emami","year":"2004","unstructured":"Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M et al. A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101: 12682\u201312687. Erratum in: Proc Natl Acad Sci USA 2004; 101: 16707.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR25","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1158\/0008-5472.CAN-08-3232","volume":"69","author":"SR Kumar","year":"2009","unstructured":"Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 2009; 69: 3736\u20133745.","journal-title":"Cancer Res"},{"key":"BFonc2015438_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/70487","volume":"23","author":"VE Velculescu","year":"1999","unstructured":"Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387\u2013388.","journal-title":"Nat Genet"},{"key":"BFonc2015438_CR27","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1073\/pnas.0504600102","volume":"102","author":"JL Teo","year":"2005","unstructured":"Teo JL, Ma H, Nguyen C, Lam C, Kahn M . Specific inhibition of CBP\/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci USA 2005; 102: 12171\u20131276.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR28","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.4155\/fmc.11.126","volume":"3","author":"M Kahn","year":"2011","unstructured":"Kahn M . Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem 2011; 3: 1745\u20131763.","journal-title":"Future Med Chem"},{"key":"BFonc2015438_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1681\/ASN.2010101079","volume":"22","author":"S Hao","year":"2011","unstructured":"Hao S, He W, Li Y, Ding H, Hou Y, Nie J et al. Targeted inhibition of \u03b2-catenin\/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011; 22: 1642\u201316453.","journal-title":"J Am Soc Nephrol"},{"key":"BFonc2015438_CR30","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1073\/pnas.1110144108","volume":"108","author":"RL Zemans","year":"2011","unstructured":"Zemans RL, Briones N, Campbell M, McClendon J, Young SK, Suzuki T et al. Neutrophil transmigration triggers repair of the lung epithelium via beta-catenin signaling. Proc Natl Acad Sci USA 2011; 108: 15990\u201315995.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5966\/sctm.2011-0033","volume":"1","author":"K Hasegawa","year":"2012","unstructured":"Hasegawa K, Yasuda SY, Teo JL, Nguyen C, McMillan M, Hsieh CL et al. Wnt signaling orchestration with a small molecule DYRK inhibitor provides long-term xeno-free human pluripotent cell expansion. Stem Cells Transl Med 2012; 1: 18\u201328.","journal-title":"Stem Cells Transl Med"},{"key":"BFonc2015438_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105\u2013111.","journal-title":"Nature"},{"key":"BFonc2015438_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature09733","volume":"469","author":"F Notta","year":"2011","unstructured":"Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362\u2013367.","journal-title":"Nature"},{"key":"BFonc2015438_CR34","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1073\/pnas.0400067101","volume":"101","author":"C Hirschmann-Jax","year":"2004","unstructured":"Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct \u201cside-population\u201d of cells with high efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228\u201314233.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1634\/stemcells.2005-0282","volume":"24","author":"N Haraguchi","year":"2006","unstructured":"Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506\u2013513.","journal-title":"Stem Cells"},{"key":"BFonc2015438_CR36","first-page":"895","volume":"63","author":"T Yamada","year":"2003","unstructured":"Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y et al. Suppression of intestinal polyposis in Mdr1-deficient ApcMin\/+ mice. Cancer Res 2003; 63: 895\u2013901.","journal-title":"Cancer Res"},{"key":"BFonc2015438_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ijc.28341","volume":"134","author":"K He","year":"2014","unstructured":"He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A . Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K\/Akt\/\u03b2-catenin\/CBP pathway. Int J Cancer 2014; 134: 43\u201354.","journal-title":"Int J Cancer"},{"key":"BFonc2015438_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748\u2013755.","journal-title":"Leukemia"},{"key":"BFonc2015438_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/156800911794328420","volume":"11","author":"YM Kim","year":"2011","unstructured":"Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D et al. The gamma catenin\/CBP complex maintains survivin transcription in \u03b2-catenin deficient\/depleted cancer cells. Curr Can Drug Targets 2011; 11: 213\u2013225.","journal-title":"Curr Can Drug Targets"},{"key":"BFonc2015438_CR40","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","volume":"9","author":"E Nicholson","year":"2009","unstructured":"Nicholson E, Holyoake T . The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma 2009; 9: S376\u2013S381.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFonc2015438_CR41","doi-asserted-by":"publisher","first-page":"e33165","DOI":"10.1371\/journal.pone.0033165","volume":"7","author":"ER Banerjee","year":"2012","unstructured":"Banerjee ER, Laflamme MA, Papayannopoulou T, Kahn M, Murry CE, Henderson WR Jr . Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model. PLoS One 2012; 7: e33165.","journal-title":"PLoS One"},{"key":"BFonc2015438_CR42","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita AC, Mita MM, Nawrocki ST, Giles FJ . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000\u20135005.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015438_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69\u201380.","journal-title":"Cell"},{"key":"BFonc2015438_CR44","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/bdd.1821","volume":"33","author":"B Xia","year":"2012","unstructured":"Xia B, Heimbach T, He H, Lin TH . Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos 2012; 33: 536\u2013549.","journal-title":"Biopharm Drug Dispos"},{"key":"BFonc2015438_CR45","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1073\/pnas.0701331104","volume":"104","author":"T Miyabayashi","year":"2007","unstructured":"Miyabayashi T, Teo JL, Yamamoto M, McMillan M, Nguyen C, Kahn M . Wnt\/beta-catenin\/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci USA 2007; 104: 5668\u20135673.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015438_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn M . Can we safely target the WNT pathway? Nat Rev Drug Discov 2014; 13: 513\u2013532.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2015438_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/cas.12471","volume":"105","author":"HJ Lenz","year":"2014","unstructured":"Lenz HJ, Kahn M . Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci 2014; 105: 1087\u20131092.","journal-title":"Cancer Sci"},{"issue":"Suppl","key":"BFonc2015438_CR48","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2013.31.15_suppl.2501","volume":"31","author":"A el-Khoueiry","year":"2013","unstructured":"el-Khoueiry A, Ning Y, Yang D, Cole S, Kahn M, Marwan Z et al. A phase I first in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 2013; 31 (Suppl): 2501 (abstract 2501).","journal-title":"J Clin Oncol"},{"key":"BFonc2015438_CR49","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","volume":"183","author":"MA Goodell","year":"1996","unstructured":"Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC . Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797\u20131806.","journal-title":"J Exp Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2015438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015438","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:06:59Z","timestamp":1647893219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":49,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2016,7,14]]}},"alternative-id":["BFonc2015438"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.438","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]},"assertion":[{"value":"28 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JLT is an equity holder in Prism Pharma Co. Ltd. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}